References in periodicals archive ?
patients experienced prolonged life and delayed disease progression) and this increased comfort levels about using CD4 T cell count as a surrogate marker for approval of future anti-HIV drugs.
In short, SMART pits immediate and uninterrupted antiretroviral therapy with a reliance on viral load as the guiding surrogate against deferred and episodic therapy with a reliance on CD4 T cell count as the guide.